288 related articles for article (PubMed ID: 17981750)
21. Smart branched polymer drug conjugates as nano-sized drug delivery systems.
Duro-Castano A; Movellan J; Vicent MJ
Biomater Sci; 2015 Oct; 3(10):1321-34. PubMed ID: 26266272
[TBL] [Abstract][Full Text] [Related]
22. Polymer-drug conjugates: present state of play and future perspectives.
Pang X; Du HL; Zhang HQ; Zhai YJ; Zhai GX
Drug Discov Today; 2013 Dec; 18(23-24):1316-22. PubMed ID: 24055841
[TBL] [Abstract][Full Text] [Related]
23. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
24. The molecularly imprinted polymer essentials: curation of anticancer, ophthalmic, and projected gene therapy drug delivery systems.
Tuwahatu CA; Yeung CC; Lam YW; Roy VAL
J Control Release; 2018 Oct; 287():24-34. PubMed ID: 30110614
[TBL] [Abstract][Full Text] [Related]
25. Targeted polymer-drug conjugates: Current progress and future perspective.
Xu H; Ma H; Yang P; Zhang X; Wu X; Yin W; Wang H; Xu D
Colloids Surf B Biointerfaces; 2015 Dec; 136():729-34. PubMed ID: 26513756
[TBL] [Abstract][Full Text] [Related]
26. Smart linkers in polymer-drug conjugates for tumor-targeted delivery.
Chang M; Zhang F; Wei T; Zuo T; Guan Y; Lin G; Shao W
J Drug Target; 2016; 24(6):475-91. PubMed ID: 26560242
[TBL] [Abstract][Full Text] [Related]
27. Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinations.
Camacho KM; Menegatti S; Mitragotri S
Nanomedicine (Lond); 2016 May; 11(9):1139-51. PubMed ID: 27079141
[TBL] [Abstract][Full Text] [Related]
28. Polymer-drug conjugates as modulators of cellular apoptosis.
Vicent MJ
AAPS J; 2007 Jun; 9(2):E200-7. PubMed ID: 17907762
[TBL] [Abstract][Full Text] [Related]
29. Polymeric anticancer drugs with pH-controlled activation.
Ulbrich K; Subr V
Adv Drug Deliv Rev; 2004 Apr; 56(7):1023-50. PubMed ID: 15066758
[TBL] [Abstract][Full Text] [Related]
30. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
31. Drug Conjugates Using Different Dynamic Covalent Bonds and their Application in Cancer Therapy.
Theodosis-Nobelos P; Charalambous D; Triantis C; Rikkou-Kalourkoti M
Curr Drug Deliv; 2020; 17(7):542-557. PubMed ID: 32384029
[TBL] [Abstract][Full Text] [Related]
32. Polymeric nano-assemblies as emerging delivery carriers for therapeutic applications: a review of recent patents.
Zhang J; Li S; Li X
Recent Pat Nanotechnol; 2009; 3(3):225-31. PubMed ID: 19958285
[TBL] [Abstract][Full Text] [Related]
33. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630
[TBL] [Abstract][Full Text] [Related]
34. Polymer therapeutics as nanomedicines: new perspectives.
Duncan R
Curr Opin Biotechnol; 2011 Aug; 22(4):492-501. PubMed ID: 21676609
[TBL] [Abstract][Full Text] [Related]
35. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
36. Polymer-drug conjugates: origins, progress to date and future directions.
Kopeček J
Adv Drug Deliv Rev; 2013 Jan; 65(1):49-59. PubMed ID: 23123294
[TBL] [Abstract][Full Text] [Related]
37. Polymer therapeutics: concepts and applications.
Haag R; Kratz F
Angew Chem Int Ed Engl; 2006 Feb; 45(8):1198-215. PubMed ID: 16444775
[TBL] [Abstract][Full Text] [Related]
38. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
39. Cancer-targeted polymeric drugs.
Luo Y; Prestwich GD
Curr Cancer Drug Targets; 2002 Sep; 2(3):209-26. PubMed ID: 12188908
[TBL] [Abstract][Full Text] [Related]
40. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Bala V; Rao S; Boyd BJ; Prestidge CA
J Control Release; 2013 Nov; 172(1):48-61. PubMed ID: 23928356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
